bioihbjkbjnl/mcl2 huggingface dataset:
Comparison of Eccentric Training on Injury Prevention and Hamstring Strength in Football Players
Condition: Sport Injury; Exercise Therapy
MeSH terms: Wounds and Injuries; Athletic Injuries
Study type: Interventional

Summary: 
      To determine the effect of the eccentric exercise training on injury prevention and hamstring
      strength in football players.
    

Detailed description: 
      Hamstrings injuries are common among footballers with a higher prevalence rate in male
      footballers. Despite the relatively high incidence of hamstring injuries in sports, no clear
      prevention methods have been identified. Most hamstring muscle injuries occur during an
      eccentric phase of any activity. Eccentric hamstring training has been used for injury
      prevention in recent years. The two distinguishing characteristics of eccentric muscle
      contractions have been well understood: 1) great force output; and 2) low energy cost to
      produce the force. Due to these distinguishing characteristics, eccentric exercise is widely
      used in injury prevention programs.

      The aim of this study is to determine the effectiveness of eccentric training as compared to
      conventional training in hamstring muscle injury prevention and strengthing in football
      players.
    

Intervention name(s): ECCENTRIC EXERCISE; CONVENTIONAL EXERCISES PROGRAM
Intervention type(s): Other; Other
Intervention description(s): Eccentric Exercise training group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, Eccentric Exercise training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. Eccentric exercise training protocol is as follow: Prone Hamstring Curl, Seated TheraBand Hamstring Curl, Exercise Ball (or glider) Bridge with Curl, Stiff-Legged Deadlift, Single Leg Deadlift, Nordic Hamstring Curl.; The participant of the Control Group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, conventional training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. The exercise will be as follow: Side Lunges, Split Squats, Calf Raises.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Remineralization of Caries Affected Dentin
Condition: Deep Caries
Study type: Interventional

Summary: 
      Remineralization of carious affected dentin
    

Detailed description: 
      Remineralization of Carious affected dentin by using Pulpine alone and combination of Pulpine
      with Polyamidoamine Dendrimer.
    

Intervention name(s): Pulpine with Polyamidoamine Dendrimer
Intervention type(s): Other
Intervention description(s): Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: split mouth design
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Alcohol, Behavior, and Brain Imaging
Condition: Alcohol Drinking; Binge Drinking; Drinking Behavior; Substance-Related Disorders; Ethanol; Physiological Effects of Drugs; Central Nervous System Depressants
MeSH terms: Substance-Related Disorders; Binge Drinking; Alcohol Drinking; Drinking Behavior
Study type: Interventional
Phase: Early Phase 1

Summary: 
      To evaluate the relationship of extraversion to both the acute subjective and behavioral
      effects of alcohol, and the neural reactivity to the anticipation of reward.
    


Intervention name(s): Ethanol; Placebo
Intervention type(s): Drug; Other
Intervention description(s): The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water; The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.
Intervention MeSH terms: Ethanol
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Basic Science
Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients
Condition: Rheumatoid Arthritis
MeSH terms: Arthritis; Arthritis, Rheumatoid
Study type: Interventional
Phase: Phase 1

Summary: 
      To study the Pharmacokinetics (PK) parameters of montelukast, flurbiprofen, midazolam,
      digoxin, pravastatin, and MTX when coadministered with BMS-986142.
    


Intervention name(s): Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142; Methotrexate, Leucovorin and BMS-986142
Intervention type(s): Drug; Drug
Intervention description(s): Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose
Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose
Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose
Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose
Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose
BMS-986142: On Days 6 through 12.; Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)
Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)
BMS-986142 on Days 6 through 10.
Intervention MeSH terms: Leucovorin; Flurbiprofen; Methotrexate; Digoxin; Midazolam; Pravastatin; Montelukast
Allocation: Non-Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Basic Science
Preimplantation Genetic Screening in Women of Advanced Maternal Age
Condition: Chromosomal Abnormalities
MeSH terms: Congenital Abnormalities; Chromosome Disorders; Chromosome Aberrations
Study type: Interventional

Summary: 
      An increased incidence of aneuploid pregnancies has been reported in women of advanced
      maternal age, with higher miscarriage rates. Cytogenetic studies in preimplantation embryos
      have shown elevated aneuploidy rate, particularly in women over 38 years. For these reasons,
      PGS has been applied to these patients to improve ongoing implantation rates, and most
      importantly, to decrease the risk of further miscarriages and affected offspring. In the past
      two years, several RCT have raised the question whether PGS is benefitial or not in AMA
      patients.

      In our experience, PGS outcome in these patients offers higher ongoing implantation rates
      than the previously published in RCT studies, where no benefits for PGS were found. In these
      papers, poor technical skills, as well as unclear patients selection could explain the
      reported lack of PGS benefits.

      Therefore, the objective of the present RCT is to analyze the outcome of IVF cycles with and
      without PGS in two age groups:

        -  Patients 38-39 years of age: 200 cyles per arm reaching embryo transfer should be
           performed

        -  Patients 40-44 years of age: 120 cycles per arm reaching embryo transfer Sample size has
           been calculated according to our retrospective experience with higher differences in
           ongoing implantation rates between cycles with and without PGS in patients of 40-44
           years of age. In all patients embryo transfer will be performed on day 5. In the PGS
           group one cell will be biopsy in embryos with ≥5 cells on day-3 and chromosomes 13, 15,
           17, 18, 21, 22, X and Y will be analyzed in two rounds. In the third round, nuclei with
           undoubtful or non-conclusive results will be analyzed using subtelomeric probes.
    


Intervention name(s): Preimplantation Genetic Screening; IVF without PGS
Intervention type(s): Procedure; Procedure
Intervention description(s): Preimplantation Genetic Screening; IVF without PGS
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Keywords: Chromosomal abnormalities in preimplantation embryos
Safety Study of BMS-823778 in Subjects With Hypercholesterolemia
Condition: Dyslipidemia
MeSH terms: Hypercholesterolemia; Dyslipidemias
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects
      on LDL cholesterol (LDL-C)
    


Intervention name(s): BMS-823778; BMS-823778; BMS-823778; Placebo
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): Capsules, Oral, 2 mg, once daily, 28 days; Capsules, Oral, 10 mg, once daily, 28 days; Capsules, Oral, 20 mg, once daily, 28 days; Capsules, Oral, 0 mg, once daily, 28 days
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Effectiveness of a Novel Device for Cervical Training in Cervicogenic Headache.
Condition: Cervicogenic Headache
MeSH terms: Post-Traumatic Headache; Headache
Study type: Interventional

Summary: 
      The purpose of this study is to evaluate the clinical results in cervical spine range of
      motion, endurance deep cervical muscles, headache impact and physical activity enjoyment by a
      training protocol with the new device for cervical treatment (CDAT) versus conventional
      training protocol (CT) in subjects with cervicogenic headache.
    

Detailed description: 
      The cervical spine is the most mobile region of the spine and must be strong enough to
      support the weight of the skull. Strength deficits of the deep cervical muscles are related
      to different clinical conditions, such as cervicogenic headache. Cervicogenic headache is a
      secondary headache defined as a unilateral headache associated with neck pain, related to a
      decreased cervical range of motion and strength deficits of the deep cervical muscles.

      Training protocols can help to improve pain, function, posture and cross-sectional area.
      However, there are no training protocols in subjects with cervicogenic headache including
      deep neck extensor and flexor muscles. The cervical device treatment (CDAT) allows us to
      train the cervical flexor and extensor muscle in a simple and comfortable way.
    

Intervention name(s): Training protocol with the cervical device for treatment (CDAT).; Conventional training protocol
Intervention type(s): Other; Other
Intervention description(s): Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.; Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: This will be a randomized controlled trial with 2 different groups
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: neck muscles; headache pain; muscle weakness; telerehabilitation; exercise therapy
To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects
Condition: Gastric Ulcer
MeSH terms: Stomach Ulcer
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral
      Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects
    

Detailed description: 
      Healthy male and female subjects (n=240) are randomized into two dose groups of 120 subjects
      each. Gastroduodenal endoscopies are performed pre-dose and post-dose, i.e., after 14 days of
      either ATB-346 (250 mg once daily) or naproxen sodium (550 mg twice daily) and the incidence
      of gastric mucosal damage is recorded for comparison between the two treatment arms.
    

Intervention name(s): ATB-346 OR Placebo; Naproxen sodium
Intervention type(s): Drug; Drug
Intervention description(s): Comparison of gastrointestinal effects; Comparison of gastrointestinal effects
Other intervention name(s): Naprosyn
Intervention MeSH terms: Naproxen
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Prevention
Keywords: Healthy Volunteers, ATB-346, Naproxen sodium, GI safety
Evaluation of PTB Screening in ANC in Lusaka, Zambia
Condition: Pulmonary Tuberculosis
MeSH terms: Tuberculosis; Tuberculosis, Pulmonary
Study type: Interventional

Summary: 
      This is a pilot pulmonary TB screening program done in three antenatal care clinics in
      Lusaka, Zambia to determine the prevalence of culture-confirmed pulmonary tuberculosis and to
      determine the sensitivity and specificity of symptom-based TB screening.
    

Detailed description: 
      5000 pregnant women attending antenatal clinics will be evaluated by piloting a TB symptom
      questionnaire as part of the general health screening done at each visit. Due to the atypical
      and subclinical presentation of TB in HIV infected patients, culture will be performed on all
      HIV-infected pregnant women, with or without symptoms, and on all symptomatic HIVnegative
      women. Referrals for TB treatment in accordance with current national guidelines will be
      offered.
    

Intervention name(s): TB screening Questionnaire; Sputum smear and culture (only in HIV negative women who are symptomatic)
Intervention type(s): Other; Other
Intervention description(s): All subjects will be screened with the questionnaire which assesses TB symptoms.; specimens for sputum microscopy and culture collected and processed in accordance with WHO TB Infection Control Guidelines
Other intervention name(s): Pilot TB symptom questionnaire
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Keywords: tuberculosis; HIV; pregnancy
Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      The objective of this study is to assess the single-dose relative bioavailability of Mylan
      Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg
      bromocriptine mesylate tablets, following the administration of a 10 mg dose, under fed
      conditions.
    


Intervention name(s): BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg; Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
Intervention type(s): Drug; Drug
Intervention description(s): 4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection; 4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Intervention MeSH terms: Bromocriptine
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
Condition: Acute Gout
MeSH terms: Gout
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute
      gout flares relieves the signs and symptoms and prevents recurrence of gout flares in
      patients with frequent flares of gout for whom non-steroidal anti-inflammatory drugs (NSAIDs)
      and/ or colchicine are contraindicated, not tolerated, or ineffective. The efficacy of
      canakinumab was compared to the corticosteroid triamcinolone acetonide.

      The purpose of the first 12-week extension study was to collect additional safety,
      tolerability and efficacy data in patients who have completed the core study CACZ885H2356.

      The purpose of the second 48 week open-label extension study was to collect additional
      long-term safety and tolerability data in patients who have completed the first extension
      study CACZ885H2356E1.
    

Detailed description: 
      Masking:

      Core: Double Blind (Subject, Investigator) Extension 1: Double Blind (Subject, Investigator)
      Extension 2: Open-label, terminated
    

Intervention name(s): Canakinumab 150 mg; Triamcinolone acetonide 40 mg; Placebo to canakinumab; Placebo to triamcinolone acetonide
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).; Triamcinolone acetonide 40 mg was supplied as a suspension.; Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.; Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
Intervention MeSH terms: Triamcinolone; Triamcinolone Acetonide; Triamcinolone hexacetonide; Antibodies, Monoclonal; Triamcinolone diacetate
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: frequent flares; gout; anti-interleukin-1β monoclonal antibody
Enhance of Language Learning With Neurostimulation
Condition: Stroke; Aphasia; Aging
MeSH terms: Aphasia
Study type: Interventional

Summary: 
      The purpose of this study is to test the effect of transcranial direct current stimulation
      over the motor cortex of the language dominant hemisphere on language learning in healthy
      subjects and stroke patients with aphasia. We hypothesize that anodal stimulation enhances
      the learning of action words compared to sham and cathodal stimulation.
    

Detailed description: 
      The motor cortex is involved at different levels of language processing. It has been
      demonstrated that the perception of action words activates motor representations in the
      language-dominant hemisphere. However, it is not known whether modulation of excitability has
      an effect on learning new action words. Thus, we hypothesize that transcranial direct current
      stimulation over the motor cortex of the language-dominant hemiphere modulates the
      acquisition of new action words. The results bear the potential to design new rehabilitative
      strategies in stroke patients with aphasia. The motor cortex might offer an access to the
      language network that can be used for interventional approaches such as neurostimulation.
    

Intervention name(s): transcranial direct current stimulation
Intervention type(s): Device
Intervention description(s): 1 mV for 20 min (verum conditions: anodal and cathodal)or 30 seconds (placebo condition: sham) during language learning , active electrode over primary motor cortex of language dominant hemisphere, reference electrode over contralateral supraorbital area
Other intervention name(s): DC Stimulator; Manufacturer:eldith -Electro-Diagnostic & Therapeutic Systems GmbH, Gustav-Kirchhoff-Straße 5, D-98693 Ilmenau; Serial number: 0006
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: stroke; aphasia; aging; language learning
Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Imitrex
Condition: Migraine
MeSH terms: Migraine Disorders
Study type: Interventional
Phase: Phase 4

Summary: 
      This is an open label, 6 month cross over study in 50 migraine patients fulfilling
      International Headache Society Classification criteria for migraine headache with and without
      aura having 2-6 migraines per month and not over 14 days a month of headaches in the previous
      3 months. Baseline Headache Impact Test -6 (HIT-6) will be obtained and 25 patients will
      administer Treximet as needed for 3 months and then 2 Aleve and 100mg Imitrex taken
      concomitantly as needed for 3 months. The other 25 patients will administer 2 Aleve and 100mg
      Imitrex taken concomitantly as needed for 3 months and then Treximet as needed for 3 months.
      In addition to Revised Patient Perception of Migraine Questionnaire (PPMQ-R)data, a detailed
      diary will be recorded regarding number of tablets taken per attack, compliance, rescue
      treatment, when patients treated their migraine attack (mild, moderate, or severe), onset of
      pain reduction (pain relief and pain free, and 24 hour pain relief and sustained pain free
      response.
    

Detailed description: 
      A migraine headache is characterized by pain felt on one and sometimes both side(s) of the
      head. Other symptoms associated with a migraine headache may include nausea, vomiting, and
      sensitivity to light and sound. A migraine can last a few hours or up to one or two days.

      Triptan medications are currently thought to be safe and effective for acute migraine
      treatment. Treximet(tm) is a triptan tablet containing a combination of sumatriptan 85mg
      (Imitrex) and naproxen sodium 500 mg.

      This combination has two methods of action for relieving a migraine headache. It targets the
      nerves and blood vessels involved in a migraine, and relieves inflammation that may cause
      migraine pain. Treximet(tm), is approved by the Food and Drug Administration.

      The purpose of this research study is to compare the effectiveness of taking Treximet(tm) as
      a combination pill to taking two Aleve(r) tablets and 100mg of Imitrex(r) as separate tablets
      taken at the same time.
    

Intervention name(s): Treximet; Imitrex and two Aleve
Intervention type(s): Drug; Drug
Intervention description(s): Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.; Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
Intervention MeSH terms: Sumatriptan
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Migraine; Headache, Migraine